Theravance Biopharma, Inc.
TBPHTheravance Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines across respiratory, infectious, and gastrointestinal diseases. It emphasizes the creation of targeted therapies with novel mechanisms of action, leveraging its proprietary drug delivery platforms and respiratory expertise to address unmet medical needs.
Company News
ResearchAndMarkets.com released a comprehensive clinical trials review for Neurogenic Orthostatic Hypotension (nOH), analyzing global trial landscapes across regions, countries, phases, and sponsor types. The report identifies key trial locations, enrollment trends, and competitive dynamics to support strategic investment decisions in the nOH the...
Theravance Biopharma reported Q2 2025 revenue of $26.2 million, driven by YUPELRI sales and a significant one-time gain from TRELEGY royalty asset sale. The company continues to focus on respiratory therapies and is advancing its ampreloxetine clinical program.
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
